Journal of Antimicrobial Chemotherapy (2000) 46, 669-683
© 2000 The British Society for Antimicrobial Chemotherapy
Review |
Application of fluoroquinolone pharmacodynamics
College of Pharmacy, University of Minnesota, Minneapolis, MN and Clinical Pharmacy, Regions Hospital, 640 Jackson Street, St Paul, MN 55101, USA
Pharmacodynamics provides a rational basis for optimizing dosing regimens by describing the relationship between drug, host and antimicrobial effect. The successful identification of meaningful pharmacodynamic outcome parameters can, therefore, greatly assist clinicians in making objective prescribing decisions rather than relying on static in vitro MIC data. While pharmacodynamic outcome parameters have been proposed for select antimicrobial agents, their clinical application remains to be defined fully. Quinolone antibiotics are generally considered to have concentration-dependent bactericidal activity and peak/MIC and AUC/MIC ratios have been identified as possible pharmacodynamic predictors of clinical and microbiological outcome as well as the development of bacterial resistance. Investigators have suggested that AUC/MIC ratios of 100–125 or peak/MIC ratios of >10 are required to predict clinical and microbiological success and to limit the development of bacterial resistance. These conclusions are derived primarily from studies of Gram-negative bacteria, and recent data suggest that these ratios may not be applicable for Streptococcus pneumoniae, where an AUC/MIC ratio of <40 appears to be a more accurate predictor. There is considerable variation in pharmacodynamic calculations and outcome parameters appear to be quinolone- and pathogen-specific. Additional prospective clinical research is needed to characterize quinolone pharmacodynamic parameters and answer unresolved questions regarding optimal pharmacodynamic outcome predictors for Gram-positive bacteria, anaerobes and atypical respiratory pathogens.
* Corresponding author. Tel: +1-651-221-3896; Fax: +1-651-292-4031; E-mail: rotsc001{at}tc.umn.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. van den Boogaard, G. S. Kibiki, E. R. Kisanga, M. J. Boeree, and R. E. Aarnoutse New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development Antimicrob. Agents Chemother., March 1, 2009; 53(3): 849 - 862. [Full Text] [PDF]
|
|
|
|
|
|
N. Venisse, N. Gregoire, M. Marliat, and W. Couet Mechanism-Based Pharmacokinetic-Pharmacodynamic Models of In Vitro Fungistatic and Fungicidal Effects against Candida albicans Antimicrob. Agents Chemother., March 1, 2008; 52(3): 937 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Olofsson, L. L. Marcusson, A. Stromback, D. Hughes, and O. Cars Dose-related selection of fluoroquinolone-resistant Escherichia coli J. Antimicrob. Chemother., October 1, 2007; 60(4): 795 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Shandil, R. Jayaram, P. Kaur, S. Gaonkar, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, and V. Balasubramanian Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis: Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo Efficacy Antimicrob. Agents Chemother., February 1, 2007; 51(2): 576 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Zhanel, J. James, S. Derkatch, N. Laing, A. M. Noreddin, and D. J. Hoban Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae J. Antimicrob. Chemother., July 1, 2006; 58(1): 112 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Kiser, D. W. Hoody, M. D. Obritsch, C. O. Wegzyn, P. C. Bauling, and D. N. Fish Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 1937 - 1945. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Olsen, M. Gentry-Nielsen, M. Yue, M. U. Snitily, and L. C. Preheim Effect of Ethanol on Fluoroquinolone Efficacy in a Rat Model of Pneumococcal Pneumonia Antimicrob. Agents Chemother., January 1, 2006; 50(1): 210 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Dupont, D. Hocquet, K. Jeannot, P. Chavanet, and P. Plesiat Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa J. Antimicrob. Chemother., April 1, 2005; 55(4): 518 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Seral, M. Barcia-Macay, M. P. Mingeot-Leclercq, P. M. Tulkens, and F. Van Bambeke Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages J. Antimicrob. Chemother., April 1, 2005; 55(4): 511 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Campion, P. J. McNamara, and M. E. Evans Evolution of Ciprofloxacin-Resistant Staphylococcus aureus in In Vitro Pharmacokinetic Environments Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4733 - 4744. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Regoes, C. Wiuff, R. M. Zappala, K. N. Garner, F. Baquero, and B. R. Levin Pharmacodynamic Functions: a Multiparameter Approach to the Design of Antibiotic Treatment Regimens Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3670 - 3676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Di Perri and S. Bonora Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? J. Antimicrob. Chemother., September 1, 2004; 54(3): 593 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Kuti, C. H. Nightingale, and D. P. Nicolau Optimizing Pharmacodynamic Target Attainment Using the MYSTIC Antibiogram: Data Collected in North America in 2002 Antimicrob. Agents Chemother., July 1, 2004; 48(7): 2464 - 2470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Yu, R. N. Greenberg, N. Zadeikis, J. E. Stout, M. M. Khashab, W. H. Olson, and A. M. Tennenberg Levofloxacin Efficacy in the Treatment of Community-Acquired Legionellosis Chest, June 1, 2004; 125(6): 2135 - 2139. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Barger, C. Fuhst, and B. Wiedemann Pharmacological indices in antibiotic therapy J. Antimicrob. Chemother., December 1, 2003; 52(6): 893 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Fish Bronchoscopic Sampling of Drug Concentrations: Penetration to Tissue Is the Issue Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1263 - 1265. [Full Text] [PDF]
|
|
|
|
|
|
R. J. O'Brien Development of Fluoroquinolones as First-line Drugs for Tuberculosis--at Long Last! Am. J. Respir. Crit. Care Med., December 1, 2003; 168(11): 1266 - 1268. [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Wilhelmus, R. L. Abshire, and B. A. Schlech Influence of Fluoroquinolone Susceptibility on the Therapeutic Response of Fluoroquinolone-Treated Bacterial Keratitis Arch Ophthalmol, September 1, 2003; 121(9): 1229 - 1233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G Zhanel and A. M Noreddin Fluoroquinolone AUIC Break Points and the Link to Bacterial Killing Rates: In Vitro Models Ann. Pharmacother., September 1, 2003; 37(9): 1331 - 1334. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Zelenitsky, R. E. Ariano, H. Iacovides, S. Sun, and G. K. M. Harding AUC0-t/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model J. Antimicrob. Chemother., April 1, 2003; 51(4): 905 - 911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Boswell, J. M. Andrews, G. Jevons, and R. Wise Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance J. Antimicrob. Chemother., October 1, 2002; 50(4): 495 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Croisier, P. Chavanet, C. Lequeu, A. Ahanou, A. Nierlich, C. Neuwirth, L. Piroth, M. Duong, M. Buisson, and H. Portier Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones J. Antimicrob. Chemother., September 1, 2002; 50(3): 349 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. J. M. Bakker-Woudenberg, M. T. ten Kate, L. Guo, P. Working, and J. W. Mouton Ciprofloxacin in Polyethylene Glycol-Coated Liposomes: Efficacy in Rat Models of Acute or Chronic Pseudomonas aeruginosa Infection Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2575 - 2581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Sanchez Navarro, M. L. Sayalero Marinero, and A. Sanchez Navarro Pharmacokinetic/pharmacodynamic modelling of ciprofloxacin 250 mg/12 h versus 500 mg/24 h for urinary infections J. Antimicrob. Chemother., July 1, 2002; 50(1): 67 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Zhanel, D. Roberts, A. Waltky, N. Laing, K. Nichol, H. Smith, A. Noreddin, T. Bellyou, and D. J. Hoban Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae J. Antimicrob. Chemother., May 1, 2002; 49(5): 807 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Ball, F. Baquero, O. Cars, T. File, J. Garau, K. Klugman, D. E. Low, E. Rubinstein, R. Wise, and T. Consensus Group on Resistance and Prescribing in R Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence J. Antimicrob. Chemother., January 1, 2002; 49(1): 31 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Thorburn and D. I. Edwards The effect of pharmacokinetics on the bactericidal activity of ciprofloxacin and sparfloxacin against Streptococcus pneumoniae and the emergence of resistance J. Antimicrob. Chemother., July 1, 2001; 48(1): 15 - 22. [Abstract] [Full Text] [PDF]
|
|